Humana, Caught up in the Metastasizing Medicare Overbilling Scandal, Enters Our Imploded Stocks

Key Takeaways

• Humana stock down 71% since Nov 2022 peak
• Medicare Advantage overbilling cost government $76‑84 billion in 2025
• Lawsuit alleges hundreds of millions in broker kickbacks
• $90 million settlement for Part D overbilling in 2024
• Revenue growth stalled; February loss reported

Summary

Humana’s Medicare Advantage business, once a profit engine, is now under intense federal scrutiny for alleged overbilling and kickback schemes. The crackdown has stalled revenue growth and led to a February loss, pushing the stock 71% lower from its November 2022 peak and into the "Imploded Stocks" category. Congressional estimates suggest Medicare Advantage overpayments added $76‑84 billion to government costs in 2025, inflating Part B premiums for seniors. Humana also settled a $90 million Part D overbilling case and faces a civil lawsuit over alleged broker kickbacks.

Pulse Analysis

The Medicare Advantage market exploded after the 2015 policy shift that let private insurers receive per‑member payments from the government. Insurers like Humana capitalized on the model by aggressively enrolling seniors and, according to congressional reports, inflating health‑risk assessments to boost monthly reimbursements. While the strategy drove double‑digit earnings growth and propelled stock prices to record highs between 2017 and 2022, it also created a systemic incentive to overstate patient conditions, a practice now under federal investigation.

Regulators are tightening oversight after audits revealed billions in excess payments. The Joint Economic Committee estimated that overpayments in 2025 alone could reach $84 billion, pushing Part B premiums up by $212 per enrollee and adding roughly $82 billion to premiums since 2016. Humana’s recent $90 million settlement for Part D overbilling and the pending civil suit alleging hundreds of millions in broker kickbacks underscore the breadth of the scandal. These legal exposures not only erode profit margins but also threaten the insurer’s reputation and its ability to attract new Medicare Advantage enrollees.

For investors, the Humana case serves as a cautionary tale about reliance on government‑funded programs with high compliance risk. As the administration pursues stricter penalties and potential clawbacks, insurers may see tighter margins, reduced bonus structures, and a slowdown in stock performance. Companies will likely need to diversify revenue streams and invest in robust compliance frameworks to mitigate future regulatory shocks, while policymakers may consider reforming payment methodologies to curb incentive‑driven overbilling.